Peroxisome proliferator activated receptors and cardiovascular disease;"Peroxisome proliferator activated receptors" e patologie cardiovascolari

Italian Heart Journal, Supplementi

Volumn 4, Issue 1, 2002, Pages 8-18

  Norata, Giuseppe Danilo ^a   Pellegatta, Fabio ^a   Catapano, Alberico Luigi ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Atherosclerosis; Diabetes mellitus; Obesity

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; CELL RECEPTOR; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG POTENTIATION; HUMAN; LIPID METABOLISM; METABOLISM; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

ANTILIPEMIC AGENTS; BEZAFIBRATE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; HUMANS; LIPID METABOLISM; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84949124332     PISSN: 15903796     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Elangbam CS, Tyler RD, Lightfoot RM. Peroxisome proliferator-activated receptors in atherosclerosis and inflammation - an update. Toxicol Pathol 2001; 29: 224-31.
2. Jones AB. Peroxisome proliferator-activated receptor (PPAR) modulators: diabetes and beyond. Med Res Rev 2001;21:540-52.
3. Diep QN, El Mabrouk M, Cohn JS, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002; 105: 2296-302.
4. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-35.
5. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 169:453-9.
6. Plutzky J. Peroxisome proliferator-activated receptors in endothelial cell biology. Curr Opin Lipidol 2001; 12: 511-8.
7. Marx N, Libby P, Plutzky J. Peroxisome proliferator-acti-vated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk 2001; 8: 203-10.
8. Qi C, Zhu Y, Reddy JK. Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys 2000; 32: 187-204.
9. Bocher V, Pineda-Torra I, Fruchart JC, Staels B. PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann NY Acad Sci 2002; 967: 7-18.
10. Staels B.Dallongeville J, Auwerx J, Schoonjans K, Leiters-dorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-93.
11. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15: 5336-48.
12. Chinetti G, Gbaguidi FG, Griglio S, et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000; 101: 2411-7.
13. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway.Nat Med 2001; 7: 53-8.
14. Schoonjans K, Watanabe M, Suzuki H, et al. Induction of the acylcoenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem 1995; 270:19269-76.
15. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 1997; 272: 28210-7.
16. Sfeir Z, Ibrahimi A, Amri E, Grimaldi P, Abumrad N. Regulation of FAT/CD36 gene expression: further evidence in support of a role of the protein in fatty acid binding/transport. Prostaglandins Leukot Essent Fatty Acids 1997; 57: 17-21.
17. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferatoractivated receptor-alpha activators. J Biol Chem 2000; 275: 36703-7.
18. Manninen V, Elo MO, Frick M H, et al. Lipid alterations and the decline in incidence of coronary heart disease risk in the Helsinki Heart Study. JAMA 1988; 260: 641-51.
19. Ruoiolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low-density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998; 32: 1648-56.
20. Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96:2137-43.
21. Behar S, Graff E, Reicher-Reiss H, et al. Low total cholesterol is associated with high total mortality in patients with coronary heart disease. The Bezafibrate Infarction Prevention (BIP) Study Group. Eur Heart J 1997; 18: 52-9.
22. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/Tex-CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
23. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT, a randomized controlled trial. JAMA 2001; 285: 1585-91.
24. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-10.
25. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z Kardiol 2001; 90 (Suppl 3): 125-32.
26. Cheng-Lai A, Levine A. Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes. Heart Dis 2000; 2: 326-33.
27. Pittas AG, Greenberg AS. Thiazolidinediones in the treatment of type 2 diabetes. Expert Opin Pharmacother 2002; 3: 529-40.
28. Martens FM, Visseren FL, Lemay J, de Koning EJ, Ra-belinkTJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62: 1463-80.
29. Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62: 1805-37.
30. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134: 61 -71.
31. Yue TITL, Chen J, Bao W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2001; 104: 2588-94.
32. Werner AL, Travaglini MT. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 2001; 21: 1082-99.
33. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-84.
34. Collins AR, Meehan WP, Kintscher U, et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low-density lipoprotein receptor-defi-cient mice. Arterioscler Thromb Vase Biol 2001; 21: 365-71.
35. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000; 106: 523-31.
36. Chen Z, Ishibashi S, Perrey S, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vase B iol 2001; 21: 372-7.
37. Tomas E, Lin YS, Dagher Z, et al. Hyperglycemia and insulin resistance: possible mechanisms. Ann NY Acad Sci 2002;967:43-51.
38. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
39. Jucker BM, Schaeffer TR, Haimbach RE, et al. Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study. Diabetes 2002; 51: 2066-73.
40. Zierath JR, Ryder JW, Doebber T, et al. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. Endocrinology 1998; 139: 5034-41.
41. Kramer D, Shapiro R, Adler A, Bush E, Rondinone CM. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism 2001; 50: 1294-300.
42. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipo-genesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994; 79: 1147-56.
43. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM. PPAR gamma 2 regulates adipose expression of the phos-phoenolpyruvate carboxykinase gene. Mol Cell Biol 1995; 15:351-7.
44. Oakes ND, Thalen PG, Jacinto SM, Ljung B. Thiazolidine-diones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 2001; 50: 1158-65.
45. Hotamisligil GS.Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
46. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994; 91: 4854-8.
47. Miles PD, Romeo OM, Higo K, Cohen A, Rafaat K, Olef-sky JM. TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 1997; 46: 1678-83.
48. Steppan CM, Bailey ST, Bhat S, et al.The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-12.
49. Kallen CB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 1996; 93: 5793-6.
50. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98: 2005-10.
51. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-53.
52. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143: 998-1007.
53. Chao L, Marcus-Samuels B, Mason MM, et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 2000; 106: 1221-8.
54. MuIIer-Wieland D, Knebel B, Avci H, et al. Insulin-regulated transcription factors: molecular link between insulin resistance and cardiovascular risk factors. Int J Obes Relat Metab Disord 2001; 25 (Suppl 1): S35-S37.
55. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-6.
56. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000; 101: 235-8.
57. Ricote M, Li AC, WillsonTM, Kelly CJ.Glass CK.The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
58. Kwak BR, Myit S, Mulhaupt F, et al. PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class II induction in atheroma-asso-ciated cells. Circ Res 2002; 90: 356-62.
59. OgiharaT, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995;8:316-20.
60. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 1996; 93: 12490-5.
61. Standaert ML, Kanoh Y, Sajan MP, Bandyopadhyay G, Farese RV. Cbl, IRS-1, and IRS-2 mediate effects of rosiglitazone on PI3K, PKC-lambda, and glucose transport in 3T3/L1 adipocytes. Endocrinology 2002; 143: 1705-16.
62. Fryer LG, Parbu-Patel A, Carling D.The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002; 277: 25226-32.
63. Boyle PJ, King AB, Olansky L, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378-96.
64. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25: 708-11.
65. Deeb SS, Fajas L, Nemoto M, et al. A Prol2AIa substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-7.
66. Wang H, Chu W, Hemphill C, Hasstedt SJ, Elbein SC. Mutation screening and association of human retinoid X receptor gamma variation with lipid levels in familial type 2 diabetes. Mol Genet Metab 2002; 76: 14-22.
67. Sramkova D, Kunesova M, Hainer V, Hill M, Vcelak J, Bendlova B. Is a Prol2Ala polymorphism of the PPARgam-ma2 gene related to obesity and type 2 diabetes mellitus in the Czech population? Ann NY Acad Sci 2002; 967: 265-73.
68. Chinetti G.Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998;273:25573-80.
69. Demetri GD, Fletcher CD, Mueller E, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with li-posarcoma. Proc Natl Acad Sci USA 1999; 96: 3951-6.
70. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4: 1046-52.
71. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J, the Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-32.
72. Gomez-Perez FJ, Fanghanel-Salmon G, Antonio Barbosa J, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002; 18: 127-34.
73. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 2002; 8: 1122-8.